Anuh Pharma surged 5.73% to Rs 160.50 at 10:58 IST on BSE after the company said it has received approval from Health Authority of Mexico for three of its Erythromycin products.
The announcement was made during market hours today, 10 April 2014.
Meanwhile, the S&P BSE Sensex was up 17.13 points or 0.08% at 22,719.47
On BSE, so far 14,598 shares were traded in the counter as against average daily volume of 12,875 shares in the past one quarter.
The stock hit a high of Rs 165 and a low of Rs 151.40 so far during the day. The stock had hit a 52-week high of Rs 168.80 on 25 February 2014. The stock had hit a 52-week low of Rs 105 on 12 August 2013.
The stock had underperformed the market over the past one month till 9 April 2014, falling 1.84% compared with the Sensex's 3.57% rise. The scrip, however, outperformed the market in past one quarter, gaining 16.77% as against Sensex's 9.6% rise.
The small-cap company has equity capital of Rs 4.17 crore. Face value per share is Rs 5.
Anuh Pharma during market hours today, 10 April 2014 said that the company has received approval from COFEPRIS (Health Authority of Mexico) GMP certificate for three of its Erythromycin products namely Erythromycin Estolate, Erythromycin Ethyl Succinate and Erythromycin Stearate.
Anuh Pharma's net profit surged 95.9% to Rs 4.31 crore on 1.9% growth in net sales to Rs 66.81 crore in Q3 December 2013 over Q3 December 2012.
Anuh Pharma is engaged in manufacturing of active pharmaceutical ingredients (APIs). The company offers bulk drugs and chemicals.
Powered by Capital Market - Live News
